Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Clinical Trials

The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma

Phase 3

Recruiting

Conditions: Basal Cell Carcinoma
BCC

Interventions: Other: SURGERY
Drug: 5-Fluorouracil

First Posted Date: 2023-11-29

Last Posted Date: 2024-01-02

Lead Sponsor: University of Aleppo

Target Recruit Count: 40

Registration Number: NCT06150144

Locations: 🇸🇾
Ibrahim Arnaout, Aleppo, Syrian Arab Republic

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Biological: JS015
Biological: Paclitaxel
Biological: Toripalimab
Drug: Irinotecan
Drug: Capecitabine
Drug: Gemcitabine
Drug: Albumin-Bound Paclitaxel
Drug: Oxaliplatin
Biological: Bevacizumab
Drug: Fluorouracil
Drug: Leucovorin

First Posted Date: 2023-11-18

Last Posted Date: 2024-12-20

Lead Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Target Recruit Count: 186

Registration Number: NCT06139211

Locations: 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

Phase 2

Recruiting

Conditions: Gastric Adenocarcinoma
HER2 Gene Mutation
Esophageal Cancer

Interventions: Drug: Pembrolizumab
Drug: Trastuzumab
Drug: Oxaliplatin
Drug: Capecitabine
Drug: 5-Fluorouracil
Drug: Docetaxel

First Posted Date: 2023-11-08

Last Posted Date: 2025-04-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 49

Registration Number: NCT06123338

Locations: 🇺🇸
Massachusetts General Hospital (Data Collection Only), Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

and more 7 locations

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Phase 2

Recruiting

Conditions: GastroEsophageal Cancer
Gastric Cancer

Interventions: Drug: Neratinib
Drug: Trastuzumab
Drug: Oxaliplatin
Drug: 5-Fluorouracil + leucovorin
Drug: Pembrolizumab

First Posted Date: 2023-10-31

Last Posted Date: 2025-04-17

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 36

Registration Number: NCT06109467

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

Phase 2

Recruiting

Conditions: Unresectable Metastatic Colorectal Cancer

Interventions: Drug: ABBV-400
Drug: Bevacizumab
Drug: Folinic Acid
Drug: Fluorouracil
Drug: Irinotecan

First Posted Date: 2023-10-30

Last Posted Date: 2025-03-25

Lead Sponsor: AbbVie

Target Recruit Count: 206

Registration Number: NCT06107413

Locations: 🇮🇱
Meir Medical Center /ID# 257089, Kfar Saba, HaMerkaz, Israel
🇺🇸
Mayo Clinic Arizona /ID# 262610, Phoenix, Arizona, United States
🇺🇸
Highlands Oncology Group, PA /ID# 259424, Springdale, Arkansas, United States

and more 57 locations

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

Phase 3

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma
Neoadjuvant Therapy
Pembrolizumab

Interventions: Drug: Pembrolizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: Nedaplatin
Drug: Nab paclitaxel
Drug: Docetaxel
Drug: Liposomal paclitaxel
Drug: Fluorouracil

First Posted Date: 2023-10-26

Last Posted Date: 2023-10-30

Lead Sponsor: Beijing Tongren Hospital

Target Recruit Count: 272

Registration Number: NCT06102395

Locations: 🇨🇳
Beijing Tongren Hospital, Beijing, Beijing, China

NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer

Phase 2

Active, not recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Durvalumab
Drug: Oxaliplatin
Drug: Irinotecan
Drug: Calcium folinate (leucovorin)
Drug: Fluorouracil
Drug: Pegylated G-CSF

First Posted Date: 2023-10-23

Last Posted Date: 2024-12-03

Lead Sponsor: Australasian Gastro-Intestinal Trials Group

Target Recruit Count: 20

Registration Number: NCT06094140

Locations: 🇦🇺
GenesisCare North Shore, Sydney, New South Wales, Australia
🇦🇺
Wollongong Hospital, Wollongong, New South Wales, Australia
🇦🇺
Warringal Private Hospital, Melbourne, Victoria, Australia